The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month ...

The Food and Drug Administration has cleared Novavax to move forward ... The event is now judged to be ALS, a rare ...

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.

Additionally, the failure of reldesemtiv, Cytokinetics’ ALS drug candidate, in a late-stage trial in the spring of 2023 ...

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company developing novel treatments for severe ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...